Phillip Suwalski

Dr. Phillip Suwalski

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in eClinicalMedicine
Verified
Journal Article
Open access
JWJanuary Weiner
January Weiner
PSPhillip Suwalski
Phillip Suwalski
MHManuel Holtgrewe
Manuel Holtgrewe
ARAlexandr Rakitko
Alexandr Rakitko
CTCharlotte Thibeault
Charlotte Thibeault
BHBettina Heidecker
Bettina Heidecker
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading to severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA) have been suggested as potential genetic host factors that affect individual immune response to SARS-CoV-2. We sought to evaluate this hypothesis by conducting a multicenter study using HLA sequencing. We analyzed the association between COVID-19 severity and HLAs in 435 individuals from Germany (n = 135), Spain (n = 133), Switzerland (n = 20) and the United States (n = 147), who had been enrolled from March 2020 to August 2020. This study included patients older than 18 years, diagnosed with COVID-19 and representing the full spectrum of the disease. Finally, we tested our results by meta-analysing data from prior genome-wide association studies (GWAS). We describe a potential association of HLA-C*04:01 with severe clinical course of COVID-19. Carriers of HLA-C*04:01 had twice the risk of intubation when infected with SARS-CoV-2 (risk ratio 1.5 [95% CI 1.1–2.1], odds ratio 3.5 [95% CI 1.9–6.6], adjusted p-value = 0.0074). These findings are based on data from four countries and corroborated by independent results from GWAS. Our findings are biologically plausible, as HLA-C*04:01 has fewer predicted bindings sites for relevant SARS-CoV-2 peptides compared to other HLA alleles. HLA-C*04:01 carrier state is associated with severe clinical course in SARS-CoV-2. Our findings suggest that HLA class I alleles have a relevant role in immune defense against SARS-CoV-2. Funded by Roche Sequencing Solutions, Inc.

21 February 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
DBDebora Brala
Debora Brala
TTTharusan Thevathasan
Tharusan Thevathasan
SGSimon Grahl
Simon Grahl
SBSteve Barrow
Steve Barrow
MVMichele Violano
Michele Violano
BHBettina Heidecker
Bettina Heidecker
Background: Inflammatory cardiomyopathy is one of the most common causes of sudden cardiac death in young adults. Diagnosis of inflammatory cardiomyopathy remains challenging, and better monitoring tools are needed. We present magnetocardiography as a method to diagnose myocardial inflammation and monitor treatment response. Methods and Results: A total of 233 patients were enrolled, with a mean age of 45 (±18) years, and 105 (45%) were women. The primary analysis included 209 adult subjects, of whom 66 (32%) were diagnosed with inflammatory cardiomyopathy, 17 (8%) were diagnosed with cardiac amyloidosis, and 35 (17%) were diagnosed with other types of nonischemic cardiomyopathy; 91 (44%) did not have cardiomyopathy. The second analysis included 13 patients with inflammatory cardiomyopathy who underwent immunosuppressive therapy after baseline magnetocardiography measurement. Finally, diagnostic accuracy of magnetocardiography was tested in 3 independent cohorts (total n=23) and 1 patient, who developed vaccine‐related myocarditis. First, we identified a magnetocardiography vector to differentiate between patients with cardiomyopathy versus patients without cardiomyopathy (vector of ≥0.051; sensitivity, 0.59; specificity, 0.95; positive predictive value, 93%; and negative predictive value, 64%). All patients with inflammatory cardiomyopathy, including a patient with mRNA vaccine‐related myocarditis, had a magnetocardiography vector ≥0.051. Second, we evaluated the ability of the magnetocardiography vector to reflect treatment response. We observed a decrease of the pathologic magnetocardiography vector toward normal in all 13 patients who were clinically improving under immunosuppressive therapy. Magnetocardiography detected treatment response as early as day 7, whereas echocardiographic detection of treatment response occurred after 1 month. The magnetocardiography vector decreased from 0.10 at baseline to 0.07 within 7 days ( P =0.010) and to 0.03 within 30 days ( P <0.001). After 30 days, left ventricular ejection fraction improved from 42.2% at baseline to 53.8% ( P <0.001). Conclusions: Magnetocardiography has the potential to be used for diagnostic screening and to monitor early treatment response. The method is valuable in inflammatory cardiomyopathy, where there is a major unmet need for early diagnosis and monitoring response to immunosuppressive therapy.

18 July 2025 in European Heart Journal
Verified
Journal Article
Closed access
Giovanni PerettoGiovanni Peretto
Giovanni Peretto
MMMarco Merlo
Marco Merlo
AAAlessandro Ambrosi
Alessandro Ambrosi
EBElena Bacigalupi
Elena Bacigalupi
Andrea VillatoreAndrea Villatore
Andrea Villatore
GSGianfranco Sinagra
Gianfranco Sinagra
Background and Aims: The prediction of the first major arrhythmic event (MAE) is still an unmet need in the recently defined scenario of non-dilated left ventricular cardiomyopathy (NDLVC). Methods: A cohort of 337 patients with NDLVC and no history of MAE was retrospectively identified at two large centres. Patient-tailored diagnostic workup included cardiac magnetic resonance (CMR), endomyocardial biopsy, and genetic testing. The primary endpoint was the occurrence of the first MAE, including sustained ventricular tachycardia (VT), ventricular fibrillation, or appropriate implantable cardioverter-defibrillator therapy, by 60-month follow-up. A pool of 216 NDLVC patients from 11 European centres served as a validation cohort. Results: In the study cohort (mean age 37 ± 15 years, 62% male), the mean left ventricular ejection fraction (LVEF) was 52 ± 8%, and 79% of patients had late gadolinium enhancement (LGE) at baseline CMR. By 60-month follow-up, 51 patients (15%) experienced a MAE. The primary endpoint was predicted by male sex [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.3–4.4, P = .007], baseline non-sustained VT (HR 3.1, 95% CI 1.7–5.6, P < .001), LVEF < 45% (HR 5.5, 95% CI 2.7–11.0, P < .001), septal (HR 2.0, 95% CI 1.0–4.0, P = .046) and ring-like pattern of LGE (HR 1.3, 95% CI .6–2.6, P = .54), pathogenic/likely pathogenic variants in guideline-defined high-risk genes (HR 4.6, 95% CI 2.3–9.1, P < .001), and biopsy/CMR-proven myocardial inflammation (HR 15.7, 95% CI 6.1–40.3, P < .001). The results were confirmed in the validation cohort (Uno’s C-index 0.81, 95% CI .75–.88). A novel risk score was subsequently derived. Conclusions: In NDLVC, male sex, non-sustained VT, LVEF < 45%, septal and ring-like LGE, high-risk genotypes, and myocardial inflammation predicted the first episode of MAE by 60 months.

14 May 2022 in eClinicalMedicine
Verified
Journal Article
Open access
RDRichard Dannebaum
Richard Dannebaum
PSPhillip Suwalski
Phillip Suwalski
HAHosseinali Asgharian
Hosseinali Asgharian
GZGracie Du Zhipei
Gracie Du Zhipei
HLHai Lin
Hai Lin
BHBettina Heidecker
Bettina Heidecker
Disease progression of subjects with coronavirus disease 2019 (COVID-19) varies dramatically. Understanding the various types of immune response to SARS-CoV-2 is critical for better clinical management of coronavirus outbreaks and to potentially improve future therapies. Disease dynamics can be characterized by deciphering the adaptive immune response. In this cross-sectional study we analyzed 117 peripheral blood immune repertoires from healthy controls and subjects with mild to severe COVID-19 disease to elucidate the interplay between B and T cells. We used an immune repertoire Primer Extension Target Enrichment method (immunoPETE) to sequence simultaneously human leukocyte antigen (HLA) restricted T cell receptor beta chain (TRB) and unrestricted T cell receptor delta chain (TRD) and immunoglobulin heavy chain (IgH) immune receptor repertoires. The distribution was analyzed of TRB, TRD and IgH clones between healthy and COVID-19 infected subjects. Using McFadden's Adjusted R2 variables were examined for a predictive model. The aim of this study is to analyze the influence of the adaptive immune repertoire on the severity of the disease (value on the World Health Organization Clinical Progression Scale) in COVID-19. Combining clinical metadata with clonotypes of three immune receptor heavy chains (TRB, TRD, and IgH), we found significant associations between COVID-19 disease severity groups and immune receptor sequences of B and T cell compartments. Logistic regression showed an increase in shared IgH clonal types and decrease of TRD in subjects with severe COVID-19. The probability of finding shared clones of TRD clonal types was highest in healthy subjects (controls). Some specific TRB clones seems to be present in severe COVID-19 (Figure S7b). The most informative models (McFadden´s Adjusted R2=0.141) linked disease severity with immune repertoire measures across all three cell types, as well as receptor-specific cell counts, highlighting the importance of multiple lymphocyte classes in disease progression. Adaptive immune receptor peripheral blood repertoire measures are associated with COVID-19 disease severity. The study was funded with grants from the Berlin Institute of Health (BIH).

23 February 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
NMNicolas Musigk
Nicolas Musigk
PSPhillip Suwalski
Phillip Suwalski
AGAinoosh Golpour
Ainoosh Golpour
DFDeLisa Fairweather
DeLisa Fairweather
KKKarin Klingel
Karin Klingel
BHBettina Heidecker
Bettina Heidecker
Infiltration of the myocardium with various cell types, cytokines and chemokines plays a crucial role in the pathogenesis of cardiomyopathies including inflammatory cardiomyopathies and myocarditis. A more comprehensive understanding of the precise immune mechanisms involved in acute and chronic myocarditis is essential to develop novel therapeutic approaches. This review offers a comprehensive overview of the current knowledge of the immune landscape in cardiomyopathies based on etiology. It identifies gaps in our knowledge about cardiac inflammation and emphasizes the need for new translational approaches to improve our understanding thus enabling development of novel early detection methods and more effective treatments.

5 June 2023 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
LSLukas Schönnagel
Lukas Schönnagel
MMMaximilian Muellner
Maximilian Muellner
TCThomas Caffard
Thomas Caffard
STSoji Tani
Soji Tani
GCGaston Camino-Willhuber
Gaston Camino-Willhuber
AHAlexander P. Hughes
Alexander P. Hughes